CA3244629A1 — Midazolam premix formulations and uses thereof
Assigned to Baxter Healthcare SA · Expires 2023-07-06 · 3y expired
What this patent protects
The present disclosure is directed to a midazolam pharmaceutical premix formulation housed in a flexible container, comprising from about 0.4 mg/ml to about 1.1 mg/ml midazolam hydrochloride and sodium chloride, wherein the formulation has a pH from about 2.7 to about 3.5. Also d…
USPTO Abstract
The present disclosure is directed to a midazolam pharmaceutical premix formulation housed in a flexible container, comprising from about 0.4 mg/ml to about 1.1 mg/ml midazolam hydrochloride and sodium chloride, wherein the formulation has a pH from about 2.7 to about 3.5. Also disclosed herein are methods of sedating a human subject in need thereof using the premix formulation.
Drugs covered by this patent
- Versed (midazolam) · Generic (originally Roche)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.